Effect of Screening on Ovarian Cancer Mortality

Buys, Saundra S.; Partridge, Edward E.; Black, Amanda; Johnson, Christine Cole; Lamerato, Lois; Isaacs, Claudine; Reding, Douglas J.; Greenlee, Robert T.; Yokochi, Lance; Kessel, Bruce; Crawford, E. David; Church, Timothy R.; Andriole, Gerald L.; Weissfeld, Joel L.; Fouad, Mona N.; Chia, David; O’Brien, Barbara; Ragard, Lawrence R.; Clapp, Jonathan D.; Rathmell, Joshua M.; Riley, Thomas L.; Hartge, Patricia; Pinsky, Paul F.; Zhu, Claire S.; Izmirlian, Grant; Kramer, Barnett S.; Miller, Anthony B.; Xu, Jian; Prorok, Philip C.; Gohagan, John K.; Berg, Christine D.

doi:10.1001/jama.2011.766

Cited by 1,097 publications

(421 citation statements)

References 23 publications

Supporting

Mentioning

400

Contrasting

Unclassified

Order By: Relevance

“…The median number of NAC cycles in the whole population was 6 (range 4-7) - 4 (range 3-4) in group 1 and 6 (range 6-7) in group 2. The median number of cycles of adjuvant chemotherapy after IDS for the whole study population was 3 [2,3,4]. There was no statistically significant difference between both groups (p = 0.14).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?

et al. 2016

View full text Add to dashboard Cite

Objective: To evaluate the overall survival (OS) of patients with initially inoperable advanced ovarian cancer, tubal carcinoma, or primary peritoneal carcinoma of stages III or IV undergoing neoadjuvant chemotherapy (NAC) followed by cytoreductive surgery, according to the number of cycles performed. Methods: This retrospective study was conducted in three main oncology centres in the east of France, reviewing the charts of all patients who underwent NAC between January 1, 1998 and October 31, 2012. We performed an OS analysis using multivariate Cox regression models adjusted for potential confounders. We also analysed progression-free survival (PFS) as well as chemotherapy- and surgery-related morbidity. Results: Of the 204 patients included, 75 (36.8%) underwent ≤4 NAC cycles and 129 (63.2%) ≥5 NAC cycles. Characteristic data were similar in the two groups. Five-year OS was 35.0 and 25.8%, respectively. This difference was non-significant [HR = 1.06 (0.70-1.59), p = 0.79]. We also found no differences in PFS or morbidity between the two groups. Conclusions: The number of NAC cycles does not seem to play a role in the OS of patients with advanced ovarian cancer. Further evidence and prospective data are needed to assess the value of a high/low number of NAC cycles among these patients.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Approximately 75% of new diagnoses are made at FIGO stage III or IV [2], with an overall 5-year survival rate of about 37% [3]. Neither screening methods nor prevention have been shown to be effective [4,5]. …”

Section: Introductionmentioning

confidence: 99%

Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?

et al. 2016

View full text Add to dashboard Cite

show abstract

“…It is especially important to survey women with HBOC after a breast cancer diagnosis because many of them will survive their breast cancer but remain at risk for ovarian cancer, which has a higher mortality rate. Furthermore, current screening protocols for ovarian cancer, including transvaginal ultrasound and monitoring of serum CA-125 concentration, lack sensitivity and specificity and do not reduce the overall risk for mortality [34]. Bilateral salpingo-oophorectomy has been well established as a successful method for the prevention of ovarian and fallopian tube cancers in BRCA1 and BRCA2 carriers.…”

Section: Discussionmentioning

confidence: 99%

Hereditary Cancer-Associated Mutations in Women Diagnosed with Two Primary Cancers: An Opportunity to Identify Hereditary Cancer Syndromes after the First Cancer Diagnosis

Saam

Moyes²,

Landon³

et al. 2014

Oncology

View full text Add to dashboard Cite

Objectives: Patients with hereditary cancer syndromes are at high risk for a second primary cancer. Early identification of these patients after an initial cancer diagnosis is the key to implementing cancer risk-reducing strategies. Methods: A commercial laboratory database was searched for women with a history of both breast and ovarian or colorectal and endometrial cancer who underwent genetic testing for hereditary breast and ovarian cancer (HBOC) or Lynch syndrome (LS). Results: Among women with both breast and ovarian cancer, 22.4% (2,237/9,982) had a BRCA1 or BRCA2 mutation. Among women with both colorectal and ovarian cancer, 28.1% (264/941) had a mutation associated with LS. In 66.6% of BRCA1 or BRCA2 mutation carriers and in 58.3% of LS mutation carriers, >5 years passed between the cancer diagnoses. Of patients with HBOC and LS, 56 and 65.2%, respectively, met the National Comprehensive Cancer Network guidelines for hereditary cancer testing after their initial diagnosis based on their personal cancer history alone. Conclusions: A substantial number of women tested for LS or HBOC after being diagnosed with two successive primary cancers were diagnosed with a hereditary cancer syndrome. In many cases, the time interval between the diagnoses was long enough to allow for the implementation of surveillance and/or prophylactic measures. © 2014 S. Karger AG, Basel

show abstract

“…The performance characteristics of screening strategies in ovarian cancer along with their cost effectiveness have been evaluated in two large screening studies [10][11]. The PLCO study reported that simultaneous screening with CA125 and transvaginal ultrasound did not reduce ovarian cancer mortality and in fact, the diagnostic evaluation following the false positive result was associated with complications [10].…”

Section: Introductionmentioning

confidence: 99%

“…The PLCO study reported that simultaneous screening with CA125 and transvaginal ultrasound did not reduce ovarian cancer mortality and in fact, the diagnostic evaluation following the false positive result was associated with complications [10]. It is yet to be determined whether the UKCTOCS trial has demonstrated a reduction in mortality or a stage shift, as data from long-term follow-up are awaited [11].…”

Section: Introductionmentioning

confidence: 99%

Vibrational biospectroscopy coupled with multivariate analysis extracts potentially diagnostic features in blood plasma/serum of ovarian cancer patients

Owens

Gajjar

Trevisan

et al. 2013

Journal of Biophotonics

View full text Add to dashboard Cite

Despite numerous advances in "omics" research, early detection of ovarian cancer still remains a challenge. The aim of this study was to determine whether attenuated total reflection Fourier-transform infrared (ATR-FTIR) or Raman spectroscopy could characterise alterations in the biomolecular signatures of human blood plasma/serum obtained from ovarian cancer patients compared to non-cancer controls. Blood samples isolated from ovarian cancer patients (n = 30) and healthy controls (n = 30) were analysed using ATR-FTIR spectroscopy. For comparison, a smaller cohort of samples (n = 8) were analysed using an InVia Renishaw Raman spectrometer. Resultant spectra were pre-processed prior to being inputted into principal component analysis (PCA) and linear discriminant analysis (LDA). Statistically significant differences (P < 0.001) were observed between spectra of ovarian cancer versus control subjects for both biospectroscopy methods. Using a support vector machine classifier for Raman spectra of blood plasma, a diagnostic accuracy of 74% was achieved, while the same classifier showed 93.3% accuracy for IR spectra of blood plasma. These observations suggest that a biospectroscopy approach could be applied to identify spectral alterations associated with the presence of insidious ovarian cancer.

show abstract

Effect of Screening on Ovarian Cancer Mortality

Cited by 1,097 publications

References 23 publications

Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?

Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?

Hereditary Cancer-Associated Mutations in Women Diagnosed with Two Primary Cancers: An Opportunity to Identify Hereditary Cancer Syndromes after the First Cancer Diagnosis

Vibrational biospectroscopy coupled with multivariate analysis extracts potentially diagnostic features in blood plasma/serum of ovarian cancer patients

Contact Info

Product

Resources

About